Organogenesis HoldingsSTU:2PQ +0.95%67 Gross Margin % is 28.90% as of Mar. 2026, which is 61% below its 10-year median of 74.81. GuruFocus rates STU:2PQ with a GF Score™ of 67/100 and a GF Value™ of €2.72 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 936 Drug Manufacturers companies, Organogenesis Holdings ranks better than 85.47% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Organogenesis Holdings had a gross margin of 28.90% for the quarter that ended in Mar. 2026 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Organogenesis Holdings Gross Margin % Related Terms
Organogenesis Holdings Gross Margin % Historical Data
* Premium members only.
The historical data trend for Organogenesis Holdings's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:2PQ vs TKNO, AKBA, SIGA: Gross Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Organogenesis Holdings Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Organogenesis Holdings's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Organogenesis Holdings (STU:2PQ) has a Gross Margin % of 28.90% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Organogenesis Holdings and its competitors. This is 61% below median its historical median of 74.81. Over the past decade, Organogenesis Holdings' Gross Margin % has ranged from 64.43 to 76.71. According to the industry distribution chart, Organogenesis Holdings ranks #136 out of 936 companies in the Drug Manufacturers industry, placing it in the top 14.5%.
Is Organogenesis Holdings' Gross Margin % too high?
Organogenesis Holdings' current Gross Margin % of 28.90% is 61% below median its 10-year median of 74.81. Over the past 10 years, this metric has ranged from a low of 64.43 to a high of 76.71. The Drug Manufacturers industry median Gross Margin % is 48.50. Organogenesis Holdings' value of 28.90% is 40.4% below this industry median. Based on the distribution chart, Organogenesis Holdings ranks #136 out of 936 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Organogenesis Holdings has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' Gross Margin % compare to TKNO and AKBA?
According to the Drug Manufacturers industry distribution chart, Organogenesis Holdings ranks #136 out of 936 companies for Gross Margin %. This places Organogenesis Holdings in the top 15% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 48.50. Organogenesis Holdings' value of 28.90% is 40.4% below this benchmark. Historically, Organogenesis Holdings' own Gross Margin % has ranged from 64.43 to 76.71 over the past decade. While the company's 10-year median is 74.81 vs. the industry median of 48.50, Organogenesis Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.50, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Organogenesis Holdings's current Gross Margin % of 28.90% is 40.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Organogenesis Holdings and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Organogenesis Holdings's current Gross Margin % is 28.90%, which is 61% below median its own 10-year median of 74.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (STU:2PQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.72, compared to a current price of €2.12 — trading 22.1% below its estimated fair value. The current Gross Margin % is 28.90%, which is 61% below median its 10-year median of 74.81 and 40.4% below the Drug Manufacturers industry median of 48.50. Organogenesis Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Organogenesis Holdings (STU:2PQ), the current Gross Margin % is 28.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Organogenesis Holdings (STU:2PQ) Overvalued in 2026?
Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued.
The current stock price of €2.12 is trading 22.1% below its estimated GF Value™ of €2.72.
GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.
Key valuation signals for STU:2PQ:
Gross Margin %: 28.90% (61% below median its 10-year median of 74.81)
GF Value™: €2.72 vs. price of €2.12 (22.1% below fair value)
Industry Position: 40.4% below the Drug Manufacturers median (#136 of 936)
No single metric tells the full story. See the STU:2PQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
67GF Score
Get the complete analysis for STU:2PQ
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:2PQ has been successfully added to your 
